Physician profile
Amanda Dendis
NPI 1881160695
$4,955.36
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,010 · 2022: $2,408 · 2023: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $553.68 | 2021-2023 | |
| Acadia Pharmaceuticals INC | $300.82 | 2021-2023 | Nuplazid |
| Amgen INC. | $298.71 | 2021-2022 | |
| Ucb, INC. | $295.71 | 2021-2023 | Briviact |
| Biohaven Pharmaceuticals, INC. | $295.35 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $294.18 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $156.22 | 2021-2023 | Austedo |
| Genzyme Corporation | $147.30 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $145.42 | 2023 | Aptiom |
| Argenx US, INC. | $133.91 | 2022-2023 | Vyvgart |
| Silk Road Medical, INC. | $127.62 | 2022 | |
| Janssen Pharmaceuticals, INC | $124.28 | 2021-2023 | Ponvory |
| Alexion Pharmaceuticals, INC. | $120.81 | 2021-2023 | Ultomiris |
| Lundbeck LLC | $116.97 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $115.33 | 2022-2023 | Onpattro |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Dendis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.